within Pharmacolibrary.Drugs.ATC.V;

model V01AA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.02,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Grass pollen extract (ATC code V01AA02) is an allergen-derived immunotherapy used for the treatment of allergic rhinitis and conjunctivitis caused by grass pollen allergy. It is administered as an allergen-specific immunotherapy to modify the immune system’s response to grass pollen allergens. The drug is generally used as subcutaneous injections or sublingual tablets/drops for desensitization therapy. It is approved and in use for management of grass pollen allergy symptoms.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic data exist for grass pollen allergen extracts. The product generally comprises protein and glycoprotein antigens which are intended to stimulate immune tolerance, not to follow standard systemic pharmacokinetics.</p><h4>References</h4><ol><li><p>Dominicus, R (2012). 3-years&#x27; long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. <i>European annals of allergy and clinical immunology</i> 44(3) 135–140. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22905596/&quot;>https://pubmed.ncbi.nlm.nih.gov/22905596</a></p></li><li><p>Kamal, MA, et al., &amp; Davis, JD (2022). Pharmacokinetics and Concentration-Response of Dupilumab in Patients With Seasonal Allergic Rhinitis. <i>Journal of clinical pharmacology</i> 62(5) 689–695. DOI:<a href=&quot;https://doi.org/10.1002/jcph.2004&quot;>10.1002/jcph.2004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34791679/&quot;>https://pubmed.ncbi.nlm.nih.gov/34791679</a></p></li><li><p>Wahn, U, et al., &amp; Bufe, A (2012). High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. <i>The Journal of allergy and clinical immunology</i> 130(4) 886–93.e5. DOI:<a href=&quot;https://doi.org/10.1016/j.jaci.2012.06.047&quot;>10.1016/j.jaci.2012.06.047</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22939758/&quot;>https://pubmed.ncbi.nlm.nih.gov/22939758</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V01AA02;
